A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Condition: Neoplasms Intervention: Drug: VIP236 Sponsor: Vincerx Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants
Condition: Healthy Interventions: Drug: CK-0045; Drug: Placebo Sponsors: Cytoki Pharma; SGS Life Sciences, a division of SGS Belgium NV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
New Publication Validates SeptiCyte RAPID as a Triaging Tool for COVID-19 Patients
SEATTLE and BRISBANE, Australia, Feb. 2, 2023. Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the publication of a study in Scientific Reports, a journal in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
CARLSBAD, Calif., Feb. 1, 2023. Ionis Pharmaceuticals, Inc. today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 1, 2023 Category: Pharmaceuticals Source Type: clinical trials
